Table 2.
The SFHs of which copy number status were associated with patient survival
| Chr | Start pos | End pos | p value | Presented gene set | Number of overlapped genes | |
|---|---|---|---|---|---|---|
| Gain |
|
|
|
|
|
|
| 19 |
41.38 |
41.63 |
2.6E-04 |
mf |
Oxygen binding |
2 |
| 19 |
43.23 |
44.29 |
0.001 |
bp |
Defense response |
4 |
| 19 |
54.72 |
55.11 |
0.002 |
bp |
Defense response |
6 |
| 19 |
54.72 |
55.11 |
0.002 |
bp |
Cell surface receptor linked Signaling pathway |
6 |
| 19 |
40.09 |
40.23 |
0.003 |
mf |
Lysophospholipase activity |
2 |
| 19 |
40.09 |
40.23 |
0.003 |
mf |
Carboxylesterase activity |
2 |
| 19 |
39.41 |
39.52 |
0.004 |
cc |
SCF ubiquitin ligase complex |
2 |
| 19 |
39.41 |
39.52 |
0.004 |
mf |
Glycoprotein binding |
2 |
| 19 |
51.63 |
52.15 |
0.007 |
mf |
Sugar binding |
9 |
| 19 |
54.78 |
55.38 |
0.007 |
bp |
Regulation of immune response |
8 |
| 19 |
51.63 |
52.27 |
0.007 |
bp |
Cell adhesion |
11 |
| 19 |
42.18 |
44.32 |
0.007 |
cc |
Anchored to membrane |
9 |
| 19 |
54.72 |
55.55 |
0.007 |
mf |
Transmembrane receptor activity |
8 |
| 19 |
54.80 |
55.30 |
0.007 |
mf |
Antigen binding |
5 |
| 19 |
54.78 |
55.42 |
0.007 |
bp |
Cellular defense response |
5 |
| 19 |
54.72 |
55.55 |
0.007 |
cc |
Integral to plasma membrane |
12 |
| 19 |
58.55 |
59.08 |
0.007 |
bp |
Viral reproduction |
7 |
| 19 |
54.78 |
55.40 |
0.007 |
bp |
Immune response |
6 |
| 19 |
50.86 |
51.59 |
0.008 |
mf |
Peptidase activity |
17 |
| 19 |
45.41 |
45.45 |
0.008 |
mf |
Lipid transporter activity |
2 |
| Loss |
|
|
|
|
|
|
| 8 |
11.83 |
12.18 |
2.4E-04 |
bp |
Defense response to bacterium |
4 |
| 4 |
55.10 |
55.99 |
0.001 |
bp |
Vascular endothelial growth Factor receptor signaling pathway |
2 |
| 4 |
55.10 |
55.99 |
0.001 |
mf |
Growth factor binding |
2 |
| 8 |
22.88 |
23.08 |
0.001 |
mf |
Caspase activator activity |
2 |
| 8 |
22.30 |
23.02 |
0.002 |
bp |
Apoptosis |
5 |
| 4 |
74.61 |
74.97 |
0.003 |
bp |
Inflammatory response |
5 |
| 8 |
26.37 |
27.47 |
0.004 |
cc |
Growth cone |
3 |
| 8 |
26.37 |
27.32 |
0.004 |
bp |
Response to cocaine |
2 |
| 8 |
22.01 |
23.08 |
0.005 |
bp |
Cellular response to mechanical stimulus |
3 |
| 4 |
68.69 |
69.36 |
0.006 |
mf |
Serine-type endopeptidase activity |
5 |
| 4 |
68.69 |
69.36 |
0.006 |
bp |
Proteolysis |
5 |
| 4 |
68.69 |
69.36 |
0.006 |
mf |
Peptidase activity |
5 |
| 4 |
70.86 |
71.40 |
0.007 |
bp |
Biomineral tissue development |
5 |
| 4 |
71.06 |
71.47 |
0.007 |
bp |
Odontogenesis of dentine-containing tooth |
3 |
| 4 |
74.26 |
74.85 |
0.007 |
cc |
Platelet alpha granule lumen |
3 |
| 4 |
74.26 |
74.85 |
0.007 |
bp |
Platelet degranulation |
3 |
| 4 |
76.92 |
76.94 |
0.008 |
bp |
Defense response to virus |
2 |
| 4 |
74.70 |
75.32 |
0.008 |
bp |
Cell-cell signaling |
4 |
| 8 | 38.13 | 38.33 | 0.008 | bp | Cell growth | 2 |